Seagen (SGEN) Stock Forecast, Price & News

Seagen (NASDAQ:SGEN) Frequently Asked Questions

Is Seagen a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Seagen.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Thursday, April, 28th. The biotechnology company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.98) by $0.24. The biotechnology company earned $426.50 million during the quarter, compared to analyst estimates of $401.75 million. Seagen had a negative trailing twelve-month return on equity of 21.86% and a negative net margin of 41.32%. The company's quarterly revenue was up 28.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.67) EPS.
View Seagen's earnings history.

What guidance has Seagen issued on next quarter's earnings?

Seagen issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.67 billion-$1.75 billion, compared to the consensus revenue estimate of $1.78 billion.

What price target have analysts set for SGEN?

10 equities research analysts have issued 12-month price targets for Seagen's stock. Their forecasts range from $132.00 to $200.00. On average, they anticipate Seagen's stock price to reach $160.00 in the next year. This suggests a possible upside of 13.2% from the stock's current price.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

Who are Seagen's key executives?

Seagen's management team includes the following people:

• Dr. Clay B. Siegall Ph.D., Co-Founder, Chairman, Pres & CEO (Age 61, Pay $3.09M)
• Mr. Todd E. Simpson, Chief Financial Officer (Age 61, Pay $1.17M)
• Ms. Jean I. Liu J.D., M.S., Chief Legal Officer (Age 54, Pay $1.11M) (LinkedIn Profile)
• Mr. Charles R. Romp, Exec. VP of Commercial U.S. (Age 54, Pay $1.02M) (LinkedIn Profile)
• Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 66, Pay $1.53M) (LinkedIn Profile)
• Dr. Vaughn B. Himes Ph.D., Chief Technical Officer (Age 61)
• Peggy Pinkston, Sr. VP of Investor Relations
• Mr. David Caouette, VP of Corp. Communications
• Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. & Alliance Management (Age 50)
• Mr. Matt Skelton, VP of Marketing

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Seagen's key competitors?

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exact Sciences (EXAS), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of SGEN's competitors.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital International Investors (8.40%), BlackRock Inc. (7.44%), Wellington Management Group LLP (6.78%), Vanguard Group Inc. (6.67%), Primecap Management Co. CA (2.51%) and State Street Corp (1.92%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends for Seagen.

Which major investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Mirae Asset Global Investments Co. Ltd., TD Asset Management Inc., UBS Group AG, First Trust Advisors LP, Tobam, Tekla Capital Management LLC, and Rhenman & Partners Asset Management AB. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

Which major investors are buying Seagen stock?

SGEN stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Woodline Partners LP, BlackRock Inc., Capital Group Private Client Services Inc., Eagle Health Investments LP, Artal Group S.A., and Vanguard Group Inc..
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $141.39.

How much money does Seagen make?

Seagen has a market capitalization of $26.03 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674.47 million in net income (profit) each year or ($3.770010) on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,675 workers across the globe.

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

When was Seagen founded?

Seagen was founded in 1998.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at (425) 527-4000, via email at [email protected], or via fax at 425-527-4001.